Distinct Roles of Molecular Chaperones HSP90α and HSP90β in the Biogenesis of KCNQ4 Channels

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Gao, Yanhong ^a   Yechikov, Sergey ^a   Vazquez, Ana E ^a   Chen, Dongyang ^a   Nie, Liping ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEAT SHOCK PROTEIN 40; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90ALPHA; HEAT SHOCK PROTEIN 90BETA; ISOPROTEIN; POTASSIUM CHANNEL KCNQ4; UNCLASSIFIED DRUG;

ARTICLE; BIOGENESIS; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; HOMEOSTASIS; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; UPREGULATION;

CELL MEMBRANE; HEARING LOSS, SENSORINEURAL; HEK293 CELLS; HOMEODOMAIN PROTEINS; HOMEOSTASIS; HSP40 HEAT-SHOCK PROTEINS; HSP70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; ION CHANNEL GATING; KCNQ POTASSIUM CHANNELS; MEMBRANE POTENTIALS; MUTATION, MISSENSE; PROTEIN TRANSPORT; PROTEOLYSIS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES;

EID: 84874215357     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057282     Document Type: Article

References (53)

1. Holt JR, Stauffer EA, Abraham D, Geleoc GS, (2007) Dominant-negative inhibition of M-like potassium conductances in hair cells of the mouse inner ear. J Neurosci 27: 8940-8951.
2. Kharkovets T, Dedek K, Maier H, Schweizer M, Khimich D, et al. (2006) Mice with altered KCNQ4 K+ channels implicate sensory outer hair cells in human progressive deafness. EMBO J 25: 642-652.
3. Kubisch C, Schroeder BC, Friedrich T, Lutjohann B, El-Amraoui A, et al. (1999) KCNQ4, a novel potassium channel expressed in sensory outer hair cells, is mutated in dominant deafness. Cell 96: 437-446.
4. Oliver D, Knipper M, Derst C, Fakler B, (2003) Resting potential and submembrane calcium concentration of inner hair cells in the isolated mouse cochlea are set by KCNQ-type potassium channels. J Neurosci 23: 2141-2149.
5. Wangemann P, (2006) Supporting sensory transduction: cochlear fluid homeostasis and the endocochlear potential. J Physiol 576: 11-21.
6. Smith RJH, Hildebrand M (1993) DFNA2 Nonsyndromic Hearing Loss. In: Pagon RA, Bird TD, Dolan CR, Stephens K, Adam MP, editors. GeneReviews. Seattle (WA).
7. Talebizadeh Z, Kelley PM, Askew JW, Beisel KW, Smith SD, (1999) Novel mutation in the KCNQ4 gene in a large kindred with dominant progressive hearing loss. Hum Mutat 14: 493-501.
8. Van Hauwe P, Coucke PJ, Ensink RJ, Huygen P, Cremers CW, et al. (2000) Mutations in the KCNQ4 K+ channel gene, responsible for autosomal dominant hearing loss, cluster in the channel pore region. Am J Med Genet 93: 184-187.
9. Akita J, Abe S, Shinkawa H, Kimberling WJ, Usami S, (2001) Clinical and genetic features of nonsyndromic autosomal dominant sensorineural hearing loss: KCNQ4 is a gene responsible in Japanese. J Hum Genet 46: 355-361.
10. Van Camp G, Coucke PJ, Akita J, Fransen E, Abe S, et al. (2002) A mutational hot spot in the KCNQ4 gene responsible for autosomal dominant hearing impairment. Hum Mutat 20: 15-19.
11. Topsakal V, Pennings RJ, te Brinke H, Hamel B, Huygen PL, et al. (2005) Phenotype determination guides swift genotyping of a DFNA2/KCNQ4 family with a hot spot mutation (W276S). Otol Neurotol 26: 52-58.
12. Kamada F, Kure S, Kudo T, Suzuki Y, Oshima T, et al. (2006) A novel KCNQ4 one-base deletion in a large pedigree with hearing loss: implication for the genotype-phenotype correlation. J Hum Genet 51: 455-460.
13. Su CC, Yang JJ, Shieh JC, Su MC, Li SY, (2007) Identification of novel mutations in the KCNQ4 gene of patients with nonsyndromic deafness from Taiwan. Audiol Neurootol 12: 20-26.
14. Hildebrand MS, Tack D, McMordie SJ, DeLuca A, Hur IA, et al. (2008) Audioprofile-directed screening identifies novel mutations in KCNQ4 causing hearing loss at the DFNA2 locus. Genet Med 10: 797-804.
15. Mencia A, Gonzalez-Nieto D, Modamio-Hoybjor S, Etxeberria A, Aranguez G, et al. (2008) A novel KCNQ4 pore-region mutation (p.G296S) causes deafness by impairing cell-surface channel expression. Hum Genet 123: 41-53.
16. Nie L, (2008) KCNQ4 mutations associated with nonsyndromic progressive sensorineural hearing loss. Curr Opin Otolaryngol Head Neck Surg 16: 441-444.
17. Arnett J, Emery SB, Kim TB, Boerst AK, Lee K, et al. (2011) Autosomal dominant progressive sensorineural hearing loss due to a novel mutation in the KCNQ4 gene. Arch Otolaryngol Head Neck Surg 137: 54-59.
18. Baek JI, Park HJ, Park K, Choi SJ, Lee KY, et al. (2011) Pathogenic effects of a novel mutation (c.664_681del) in KCNQ4 channels associated with auditory pathology. Biochim Biophys Acta 1812: 536-543.
19. de Heer AM, Schraders M, Oostrik J, Hoefsloot L, Huygen PL, et al. (2011) Audioprofile-directed successful mutation analysis in a DFNA2/KCNQ4 (p.Leu274His) family. Ann Otol Rhinol Laryngol 120: 243-248.
20. Kim HJ, Lv P, Sihn CR, Yamoah EN, (2011) Cellular and molecular mechanisms of autosomal dominant form of progressive hearing loss, DFNA2. J Biol Chem 286: 1517-1527.
21. Namba K, Mutai H, Kaneko H, Hashimoto S, Matsunaga T, (2012) In silico modeling of the pore region of a KCNQ4 missense mutant from a patient with hearing loss. BMC Res Notes 5: 145.
22. Robbins J, (2001) KCNQ potassium channels: physiology, pathophysiology, and pharmacology. Pharmacol Ther 90: 1-19.
23. Deutsch C, (2002) Potassium channel ontogeny. Annu Rev Physiol 64: 19-46.
24. Hartl FU, Hayer-Hartl M, (2009) Converging concepts of protein folding in vitro and in vivo. Nat Struct Mol Biol 16: 574-581.
25. Pratt WB, Toft DO, (2003) Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood) 228: 111-133.
26. Taipale M, Jarosz DF, Lindquist S, (2010) HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 11: 515-528.
27. Zuehlke A, Johnson JL, (2010) Hsp90 and co-chaperones twist the functions of diverse client proteins. Biopolymers 93: 211-217.
28. Hinzpeter A, Lipecka J, Brouillard F, Baudoin-Legros M, Dadlez M, et al. (2006) Association between Hsp90 and the ClC-2 chloride channel upregulates channel function. Am J Physiol Cell Physiol 290: C45-56.
29. Ficker E, Dennis AT, Wang L, Brown AM, (2003) Role of the cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel HERG. Circ Res 92: e87-100.
30. Peterson LB, Eskew JD, Vielhauer GA, Blagg BS, (2012) The hERG channel is dependent upon the Hsp90alpha isoform for maturation and trafficking. Mol Pharm 9: 1841-1846.
31. Yan FF, Pratt EB, Chen PC, Wang F, Skach WR, et al. (2010) Role of Hsp90 in biogenesis of the beta-cell ATP-sensitive potassium channel complex. Mol Biol Cell 21: 1945-1954.
32. Dennis A, Wang L, Wan X, Ficker E, (2007) hERG channel trafficking: novel targets in drug-induced long QT syndrome. Biochem Soc Trans 35: 1060-1063.
33. Guo J, Zhang X, Hu Z, Zhuang Z, Zhu Z, et al. (2012) A422T mutation in HERG potassium channel retained in ER is rescurable by pharmacologic or molecular chaperones. Biochem Biophys Res Commun 422: 305-310.
34. Sun F, Mi Z, Condliffe SB, Bertrand CA, Gong X, et al. (2008) Chaperone displacement from mutant cystic fibrosis transmembrane conductance regulator restores its function in human airway epithelia. FASEB J 22: 3255-3263.
35. Wang X, Venable J, LaPointe P, Hutt DM, Koulov AV, et al. (2006) Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell 127: 803-815.
36. Yang B, Zhao D, Verkman AS, (2009) Hsp90 inhibitor partially corrects nephrogenic diabetes insipidus in a conditional knock-in mouse model of aquaporin-2 mutation. FASEB J 23: 503-512.
37. Keller A, Nesvizhskii AI, Kolker E, Aebersold R, (2002) Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem 74: 5383-5392.
38. Hahn JS, (2009) The Hsp90 chaperone machinery: from structure to drug development. BMB Rep 42: 623-630.
39. Johnson JL, (2012) Evolution and function of diverse Hsp90 homologs and cochaperone proteins. Biochim Biophys Acta 1823: 607-613.
40. Eustace BK, Sakurai T, Stewart JK, Yimlamai D, Unger C, et al. (2004) Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat Cell Biol 6: 507-514.
41. Cheng CF, Fan J, Fedesco M, Guan S, Li Y, et al. (2008) Transforming growth factor alpha (TGFalpha)-stimulated secretion of HSP90alpha: using the receptor LRP-1/CD91 to promote human skin cell migration against a TGFbeta-rich environment during wound healing. Mol Cell Biol 28: 3344-3358.
42. Tsutsumi S, Scroggins B, Koga F, Lee MJ, Trepel J, et al. (2008) A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion. Oncogene 27: 2478-2487.
43. Li W, Sahu D, Tsen F, (2012) Secreted heat shock protein-90 (Hsp90) in wound healing and cancer. Biochim Biophys Acta 1823: 730-741.
44. Cortes-Gonzalez C, Barrera-Chimal J, Ibarra-Sanchez M, Gilbert M, Gamba G, et al. (2010) Opposite effect of Hsp90alpha and Hsp90beta on eNOS ability to produce nitric oxide or superoxide anion in human embryonic kidney cells. Cell Physiol Biochem 26: 657-668.
45. Theodoraki MA, Caplan AJ, (2012) Quality control and fate determination of Hsp90 client proteins. Biochim Biophys Acta 1823: 683-688.
46. Pratt WB, Morishima Y, Peng HM, Osawa Y, (2010) Proposal for a role of the Hsp90/Hsp70-based chaperone machinery in making triage decisions when proteins undergo oxidative and toxic damage. Exp Biol Med (Maywood) 235: 278-289.
47. Kundrat L, Regan L, (2010) Balance between folding and degradation for Hsp90-dependent client proteins: a key role for CHIP. Biochemistry 49: 7428-7438.
48. Trepel J, Mollapour M, Giaccone G, Neckers L, (2010) Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10: 537-549.
49. Whitesell L, Santagata S, Lin NU (2012) Inhibiting HSP90 to treat cancer: a strategy in evolution. Curr Mol Med.
50. Aridon P, Geraci F, Turturici G, D'Amelio M, Savettieri G, et al. (2011) Protective role of heat shock proteins in Parkinson's disease. Neurodegener Dis 8: 155-168.
51. Kalia SK, Kalia LV, McLean PJ, (2010) Molecular chaperones as rational drug targets for Parkinson's disease therapeutics. CNS Neurol Disord Drug Targets 9: 741-753.
52. Luo W, Sun W, Taldone T, Rodina A, Chiosis G, (2010) Heat shock protein 90 in neurodegenerative diseases. Mol Neurodegener 5: 24.
53. Neckers L, Workman P, (2012) Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res 18: 64-76.